Ведение больных внебольничной пневмонией в амбулаторных условиях


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Пневмония остается серьезной проблемой общественного здравоохранения в связи с неприемлемо высокой заболеваемостью и смертностью. К числу вопросов, требующих решения, следует прежде всего отнести трудности в установлении первоначального клинического диагноза пневмонии, стратификацию риска неблагоприятного исхода заболевания, оптимизацию выбора эмпирической антибиотикотерапии, относительную нехватку новых антибиотиков и важность знания местных особенностей микробиологической чувствительности пневмотропных микроорганизмов. В статье обсуждается проблема ведения взрослых больных внебольничной пневмонией (ВП). Представлены сведения об эпидемиологии, диагностике, стратификации больных ВП по степени риска неблагоприятного исхода заболевания с целью определения пациентов этой категории, которые могли бы получать амбулаторное лечение без ущерба конечной эффективности и безопасности, а также антибактериальной терапии больных ВП в амбулаторных условиях, в т.ч. с применением новых антибиотиков.

Полный текст

Доступ закрыт

Об авторах

А. И Синопальников

Российская медицинская академия непрерывного профессионального образования

Email: aisyn@list.ru
д.м.н., профессор, зав. кафедрой пульмонологии 125993, Россия, Москва, Баррикадная ул., 2/1, стр.1

Список литературы

  1. Niederman M.S., Bass J.B. Jr., Campbell G.D., et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-26.
  2. Pasteur L. Note on the new disease caused by the saliva of a child who died of rabies. C R Acad Sci. 1881;92:159-65. doi: 10.1016/S2352-3018(15)00108-3.
  3. Sternberg G.M. The pneumonia-coccus of Friedlander (Micrococcus Pasteuri, Sternberg). Am J Med Sci. 1885;90:106-23.
  4. Fraenkel A. Weitere Beitrage zur Lehre von den Mikrococcen der genuinen fibrinosen Pneumonie [Further contributions to the theory of Micrococci of genuine fibrinous pneumonia]. Zeitschrift filr Klinische Medicin. 1886b;i1:437-58.
  5. Osler W. The principles and practice of medicine. New York: D. Appleton and Company; 1901.
  6. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death 2013 a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71. doi: 10.1016/S0140-6736(14)61682-2.
  7. Metlay J.P, Waterer G.W., bang A.C., et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45-e67. doi: 10.1016/S0140-6736(14)61682-2.
  8. Zweigner J, Meyer E., Gastmeier P, Schwab F. Rate of antibiotic prescriptions in German outpatient care - are the guidelines followed or are they still exceeded? GMS Hyg. infect Control. 2018;13:Doc04. doi: 10.3205/dgkh000310.
  9. Socie'te' Francaise de Me'decine Ge'ne'rale. Observatoire de la Me'decine Ge'ne'ral. Donnees en consultation pour: Pneumophatie Aigue. URL: http:// omg.sfmg.org/content/donnees/donnees.php. (Accessed 28 October 2018).
  10. Lim W.S., Baudouin S.V., George R.C., et al., Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl. 3);iii1-55.
  11. Almirall J., Serra-Prat M., Bolibar i., Balasso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respir. 2017;94:299-311. doi: 10.1159/000479089.
  12. Liapikou A., Cilloniz C., Torres A. Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opin Drug Saf. 2018;17:991-1003. doi: 10.1080/14740338.2018.1519545.
  13. Trotter C.L., Stuart J.M., George G., et al. increasing hospital admissions for pneumonia, England. Emerg infect Dis. 2008;14:727-33. Doi: 10.3201/ eid1405.071011.
  14. Almirall J., Bolibar i., Vidal J., et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir. J 2000;15:757-63. doi: 10.1034/j.1399-3003.2000.15d21.x.
  15. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50. doi: 10.1056/NEJM199701233360402.
  16. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82. doi: 10.1136/thorax.58.5.377.
  17. Raut M., Schein J., Mody S., et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin. 2009;25:2151-57. doi: 10.1185/03007990903102743.
  18. Van Vugt S.F, Broekhuizen B.D., Lammens C., et al. Use of serum C-reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ. 2013;346:f2450. doi: 10.1136/bmj.f2450.
  19. Smith S.M., Fahey T., Smucny J., Becker L.A. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2014;3:CD000245. doi: 10.1002/14651858. CD000245.pub3.
  20. Schuetz P, Muller B., Christ-Crain M., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9:CD007498. doi: 10.1002/14651858.CD007498.pub2.
  21. Ranzani O.T., Taniguchi L.U., Torres A. Severity scoring systems for pneumonia: current understanding and next steps. Curr Opin Pulm Med. 2018;24:227-36. doi: 10.1097/MCP0000000000000468.
  22. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50. doi: 10.1056/NEJM199701233360402.
  23. Mandell L.A., Wunderink R.G., Anzueto A., et al. infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin infect Dis. 2007;44(Suppl. 2):27-72.
  24. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin infect Dis. 2008;47:375-84. doi: 10.1086/589754.
  25. Espana P.P, Capelastegui A., Gorordo i., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174:1249-56. doi: 10.1164/rccm.200602-177OC.
  26. Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-10. doi: 10.1001/jama.2016.0287.
  27. Chalmers J.D., Singanayagam A., Akram A.R., et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65:878-83. doi: 10.1136/ thx.2009.133280.
  28. Bauer T.T, Ewig S., Marre R., Suttorp N., Welte T: CRB-65 predicts death from community-acquired pneumonia. J intern Med. 2006;260:93-101. doi: 10.1111/j.1365-2796.2006.01657.x.
  29. Kaysin A, Viera A.J. Community-acquired pneumonia: diagnosis and management. Am Fam Physician. 2016;94:698-706.
  30. Corrales-Medina V.F, Musher D.M., Wells G.A., et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773-81. Doi: 10.1161/ CiRCUiATiONAHA.111.040766.
  31. Ewig S, Bauer T, Richter K., et al. Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J. 2013;41:917-22. doi: 10.1183/09031936.00065212.
  32. Choudhury G, Chalmers J.D., Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011;38:643-48. doi: 10.1183/09031936.00172910.
  33. Kolditz M, Ewig S., Schutte H., et al. Assessment of o xyg enation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J intern Med. 2015;278:193-202.
  34. Ewig S, Hoffken G., Kern W.V., et al. Management of adult community-acquired pneumonia and prevention - update 2016. Pneumologie. 2016;70:151-200. doi: 10.1055/s-0042-101873.
  35. Kolditz M., Braeken D., Ewig S., Rohde G. Severity assessment and the immediate and long-term prognosis in community-acquired pneumonia. Semin Respir Crit Care Med. 2016;37:886-96. doi: 10.1055/s-0036-1592127.
  36. Kolditz M., Ewig S. Community-acquired pneumonia in adults. Dtsch Arztebl int. 2017;114:838-48. doi: 10.3238/arztebl.2017.0838.
  37. Musher D.M., Thorner A.R. Community-acquired pneumonia. N Engl J Med. 2014;371:1619-28. doi: 10.1056/NEJMra1312885.
  38. Mandell L.A, Wunderink R.G., Anzueto A., et al. infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin infectDis. 2007;44(Suppl. 2):27-72.
  39. Козлов Р.С., Зырянов С.К., Синопальников А.И. и др. Резолюция совета экспертов «Эмпирическая антибактериальная терапия инфекций дыхательных путей с учетом факторов риска резистентной флоры» (28.10.2017, Москва). Справочник поликлинического врача. 2018;1:6-10.
  40. NiCE. National institute for Health and Care Excellence. Clinical Guideline [CG191]. Pneumonia in adults: diagnosis and management. Published: 3 December 2014. nice.org.uk/guidance/cg191.
  41. Cao B., Huang Y, She D.Y., et al. Diagnosis and treatment of communityacquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12:1320-60.
  42. Boyles T.H., Brink A., Calligaro G.L., et al. South African Thoracic Society; Federation of infectious Diseases Societies of Southern Africa. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9:1469-502. doi: 10.21037/jtd.2017.05.31.
  43. Correa R.A., Costa N.A., Lundgren F., et al. 2018 recommendations for the management of community acquired pneumonia. J Brasil Pneumol. 2018;44:405. doi: 10.1590/S1806-37562018000000130.
  44. Zaroff J.G., Craig T.C., Palmetto N., et al. Association of azithromycin use with cardiovascular mortality. JAMA. Network Open. 2020;3(6):e208199. doi: 10.1001/ jamanetworkopen.2020.8199.
  45. Иванчик Н.В., Чагарян А.Н., Сухорукова М.В. и др. Антибиотикорезистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПеГАС 2014-2017». Клиническая микробиология и антимикробная химиотерапия. 2019;21(3):230-37.
  46. Bjerre L.M., Verheij T.J., Kochen M.M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;(4):CD002109. doi: 10.1002/14651858.CD002109.pub3.
  47. Pakhale S., Mulpuru S., Verheij T.J., et al. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst. Rev. 2014;(10):CD002109. doi: 10.1002/14651858.CD002109.pub4.
  48. Postma D.F., van Werkhoven C.H., van Elden L.J., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312-23. Doi: 10.1056/ NEJMoa1406330.
  49. Чучалин А.Г, Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Клинические рекомендации (проект). 2019.
  50. Sivaya O., Kozlov R., Sukhorukova M., et al. Longterm surveillance of antimicrobial resistance of H. influenzae in Russia: are there any changes in ten years? ECCMiD 2016, Amsterdam, 9-12 April, Poster # EV0302.
  51. Maimon N., Nopmaneejumruslers C., Marras T.K. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J. 2008;31:1068-76. doi: 10.1183/09031936.00109007.
  52. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin infect. Dis. 2002;35:556-64. doi: 10.1086/341978.
  53. Daneman N., McGeer A., Green K., et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin infect Dis. 2006;43:432-38.
  54. Чучалин А.Г, Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике (пособие для врачей). Клиническая микробиология и антимикробная химиотерапия. 2010;12:186-225.
  55. Woodhead M., Blasi F., Ewig S. and the ERS/ESCMiD Task Force. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol infect. 2011;17(Suppl. 6):1-59. doi: 10.1111/j.1469-0691.2011.03672.x.
  56. Niederman M.S. in the Clinic: Community-Acquired Pneumonia. Ann Intern Med. 2015;163:1-17. doi: 10.7326/AITC201510060.
  57. Athlin S, Lidman C., Lundqvist A., et al. Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. Infect. Dis. (Land). 2018;50:247-72. doi: 10.1080/23744235.2017.1399316.
  58. Cilloniz C, Ewig S., Polverino E., et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J. 2012;40:931-38. doi: 10.1183/09031936.00168811.
  59. Fantin B, Aubert J.P, Unger P, et al. Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Chest. 2001;120:185-92. doi: 10.1378/chest.120.1.185.
  60. Minogue M.F, Coley C.M., Fine M.J., et al. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med. 1998;31:376-80. doi: 10.1016/s0196-0644(98)70350-6.
  61. Prina E, Ranzani O.T, Torres A. Community-acquired pneumonia. Lancet. 2015;386:1097-108. doi: 10.1016/S0140-6736(15)60733-4.
  62. Tansarli G.S., Mylonakisa E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2018;62(9):e00635-18. Doi: 10.1128/ AAC.00635-18.
  63. L pez-Alcalde J., Rodriguez-Barrientos R., Redondo-S nchez J., et al. Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. Cochrane Database Syst Rev. 2018;9:CD009070. doi: 10.1002/14651858.CD009070.pub2.
  64. Silverman M., Povitz M., Sontrop J.M., et al. Antibiotic prescribing for nonbacterial acute upper respiratory infections in elderly persons. Ann Intern Med. 2017;166:765-74. doi: 10.7326/M16-1131.
  65. McDonagh M.S., Peterson K., Winthrop K., et al. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res. 2018;46:3337-57. doi: 10.1177/0300060518782519.
  66. Froes F., Pereira J.G., Povoa P. Outpatient management of community-acquired pneumonia. Curr Opin Pulm Med. 2019;25:249-56. Doi: 10.1097/ MCP.0000000000000558.
  67. U.S. Food and Drug Administration. FDA approves new antibiotic to treat community-acquired bacterial pneumonia. URL: www.fda.gov/news-events/ pressannouncements/fda-approves-new-antibiotic-treat-community-acquiredbacterial-pneumonia.
  68. Rodvold K.A. Introduction: lefamulin and pharmacokinetic/ pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother. 2019;74(Suppl3):iii2-4. Doi: 10.1093/ jac/dkz084.
  69. File T.M., Goldberg L., Das A., et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis. 2019;69:1856-67. doi: 10.1093/cid/ ciz090.
  70. Alexander E., Goldberg L., Das A.F., et al. Oral lefamulin vs moxi oxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. [e-pub Sep. 27, 2019].
  71. Nabriva Therapeutics. Nabriva Therapeutics receives U.S. FDA approval of Xenleta™ (lefamulin) to treat community-acquired bacterial pneumonia (CABP). URL: https://investors.nabriva.com/news-releases/ news-release-details/nabriva-therapeutics-receives-us-fda-approval-xenleta.
  72. Malani P.N. Lefamulin - a new antibiotic for community-acquired pneumonia. JAMA. [e-pub Sep. 27, 2019].
  73. Teng F., Liu X., Guo S.B., et al. Community-acquired bacterial co-infection predicts severity and mortality in influenza-associated pneumonia admitted patients. J Infect Chemother. 2019;25:129-36. doi: 10.1016/j.jiac.2018.10.014.
  74. Cantan B., Luyt C.E., Martin-Loeches I. Influenza Infections and Emergent Viral Infections in Intensive Care Unit. Semin Respir Crit Care Med. 2019;40:488-97. doi: 10.1055/s-0039-1693497.
  75. Bonten M.J., Huijts S.M., Bolkenbaas M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114-25. Doi: 10.1056/ NEJMoa1408544.
  76. Frenck R.W. Jr., Gurtman A., Rubino J., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19:1296-303. doi: 10.1128/CVI.00176-12.
  77. Schwarz T.F., Flamaing J., Rumke H.C., et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >65 years. Vaccine. 2011;29:5195-202. doi: 10.1016/j.vaccine.2011.05.031.
  78. Ofori-Anyinam O., Leroux-Roels G., Drame M., et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults >50years of age: Results from a phase III, randomized, noninferiority trial. Vaccine. 2017;35:6321-28. doi: 10.1016/j.vaccine.2017.09.012.
  79. Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices (ACIP). URL: https://www. cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf.
  80. Козлов Р.С., Авдеев С.Н., Брико Н.И. и др. Вакцинопрофилактика пневмококковых инфекций у взрослых. Резолюция совета экспертов (Москва, 16 декабря 2017 г). Клиническая микробиология и антимикробная химиотерапия. 2018;20:5-8.
  81. Matanock A., Lee G., Gierke R., et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2019;68:1069-75. doi: 10.15585/mmwr.mm6846a5.
  82. Hedlund J., Kalin M., Ortqvist A. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treatedpneumonia:aetiologyandpredisposing conditions. Scand J Infect. Dis. 1997;29:387-92. doi: 10.3109/00365549709011836.
  83. Козлов Р.С., Сухорукова М.В., Сивая О.В. и др.Чувствительность к антимикробным препаратамклинических штаммов Streptococcus pneumoniae,выделенных в различных регионах РФ в 2010-2013гг. Клиническая микробиологияи анти-микробная химиотерапия. 2015;17(Приложение1):31.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2020

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах